Minophagen-C Intravenous Drip Dosage and Dilution
For adult patients with chronic liver disease, the standard dosage of Minophagen-C (Stronger Neo-Minophagen C/SNMC) is 40-100 mL per day administered as a slow intravenous drip, diluted in 250-500 mL of normal saline or 5% dextrose solution, infused over 2-4 hours.
Standard Dosing Regimens
Initial/Standard Dose
- 40 mL/day is the established baseline dose for chronic hepatitis
- Administered intravenously, typically diluted in 250-500 mL of compatible IV fluid
- Duration: 2-4 weeks initially 1, 2
Intensive/High Dose
- 100 mL/day for patients requiring more aggressive treatment or those who show insufficient response to standard dosing
- This higher dose demonstrates significantly better efficacy (52.3% improvement vs 26.1% with 40 mL/day, P=0.017) 1
- Particularly indicated for acute-onset autoimmune hepatitis or severe liver dysfunction 3
Pediatric Dosing
- 50 mL/day (approximately 2 mg/kg of glycyrrhizin) for children with liver dysfunction
- Administered for at least 1 week 4
- For acute icteric hepatitis in children, dosing should be weight-adjusted 5
Dilution and Administration
Dilution specifications:
- Minophagen-C contains 0.2% glycyrrhizin (2 mg/mL), supplemented with 2% glycine and 0.1% cysteine
- Dilute in 250-500 mL of normal saline (0.9% NaCl) or 5% dextrose in water (D5W)
- Infusion rate: Administer over 2-4 hours as a slow continuous drip
- Do not administer as a rapid bolus
Treatment Duration
- Initial course: 2-4 weeks of daily administration
- May be followed by oral glycyrrhizin maintenance therapy (GLYCYRON tablets, 9 tablets/day) for an additional 4 weeks 2
- For chronic conditions, treatment can be extended to 3 times weekly maintenance dosing 6
Monitoring Parameters
Essential monitoring during therapy:
- Liver function tests (ALT, AST, total bilirubin) - check weekly initially, then every 2 weeks 1, 3
- Target therapeutic plasma glycyrrhizin concentration: ≥5 μg/mL for optimal effect 6
- Blood pressure and electrolytes (watch for hypokalemia and sodium retention from mineralocorticoid effects)
- Renal function in patients with pre-existing kidney disease
Clinical Efficacy Thresholds
The pharmacokinetic data suggest that maintaining plasma glycyrrhizin levels near or above 5 μg/mL is necessary for sufficient hepatoprotective effects 6. The 100 mL dose achieves this threshold more reliably than lower doses, particularly in patients with impaired hepatic clearance.
Important Caveats
- Contraindications: Severe hypertension, heart failure, hypokalemia, pregnancy
- Side effects: Generally mild and reversible; withdrawal rate due to adverse effects is approximately 2% 2
- The combination of monoammonium glycyrrhizinate and cysteine (components of Minophagen-C) works synergistically through Nrf2/ARE pathway activation 7
- Higher doses (100 mL) should be reserved for patients with more severe disease or inadequate response to standard dosing, as the incremental benefit plateaus beyond this dose 1
The optimal ratio of glycyrrhizin to cysteine is 2:1 for maximal therapeutic effect 7, which is the formulation used in commercial Minophagen-C preparations.